Understanding drug targets: no such thing as bad news

Abstract: How can small-to-medium pharma and biotech companies enhance the chances of running a successful drug project and maximise the return on a limited number of assets? Having a full appreciation of the safety risks associated with proposed drug targets is a crucial element in understanding the unwanted side-effects that might stop a project in [...]

By |2018-10-01T17:36:10+00:00June 6th, 2018|Target Safety Assessments, Publications|Comments Off on Understanding drug targets: no such thing as bad news